Department of Thoracic Surgery, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital, Izmir, Turkey.
Department of Thoracic Surgery, Ege University School of Medicine, Izmir, Turkey.
BMC Surg. 2024 Sep 19;24(1):267. doi: 10.1186/s12893-024-02565-2.
The aim of combining hyperthermic intrathoracic chemotherapy (HITHOC) with surgery is to achieve local control in patients with pleural malignancies. Liver and kidney dysfunction resulting from this procedure have been reported in the literature. The objective of the study is to examine whether the laboratory abnormalities observed during the initial period persist until day 30.
The study conducted a retrospective analysis of the blood glucose levels, renal function markers, and hepatic function markers of 30 patients who underwent pleurectomy-decortication and HITHOC for pleural mesothelioma from January 2010 to April 2022. The measurements were taken in the postoperative period on the first four and 30th days. The study analyzed the initial and final laboratory results caused by the procedure.
Out of the total of 30 patients, 29, 28, 14, and 12 patients had elevated glucose levels on the first four days after the surgery, respectively. There was no association between glucose abnormalities and preoperative-postoperative diabetes mellitus. A minority of patients experienced atypical alterations in kidney and liver functions during the initial postoperative period. There was no apparent relationship between the renal and hepatic functions in the early and late periods after the surgery.
Although there were fluctuations in glucose levels and renal and hepatic functions in the early period after surgery, there were no persistent alterations in these parameters by day 30. Elevated glucose levels during the early period were not associated with the development of newly diagnosed diabetes mellitus after surgery. The findings of our study provide evidence that HITHOC is a favorable and well-tolerated treatment option for mesothelioma.
胸腔内热化疗(HITHOC)与手术联合的目的是在胸膜恶性肿瘤患者中实现局部控制。该手术会导致肝肾功能障碍,这在文献中已有报道。本研究的目的是检查手术初期观察到的实验室异常是否持续到第 30 天。
本研究对 2010 年 1 月至 2022 年 4 月期间因胸膜间皮瘤行胸膜切除术和 HITHOC 的 30 例患者的血糖水平、肾功能标志物和肝功能标志物进行了回顾性分析。在术后第 1、4 和 30 天进行测量。该研究分析了手术引起的初始和最终实验室结果。
在 30 例患者中,分别有 29、28、14 和 12 例患者在手术后的前 4 天血糖升高。血糖异常与术前术后糖尿病之间没有关联。少数患者在术后初期出现肾功能和肝功能异常。手术后早期和晚期肾功能和肝功能之间没有明显关系。
尽管手术后早期血糖水平以及肾功能和肝功能出现波动,但到第 30 天这些参数没有持续变化。早期升高的血糖水平与术后新发糖尿病的发展无关。本研究的结果表明,HITHOC 是一种治疗间皮瘤的有利且耐受良好的治疗选择。